Tuna Mutis

13.3k citations

180 papers · 9.4k indexed · 2 hit papers · h-index 50

Hematology top 0.1%
- Multiple Myeloma Research and Treatments 66
- Hematopoietic Stem Cell Transplantation 18
Immunology top 0.2%
- Immune Cell Function and Interaction 60
- Immunotherapy and Immune Responses 53
- T-cell and B-cell Immunology 41
Oncology top 0.5%
- CAR-T cell therapy research 54
- Peptidase Inhibition and Analysis 18
Physiology top 0.5%
Genetics top 1%
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 34

Co-authors: Niels W.C.J. van de Donk Els Goulmy Henk M. Lokhorst Paul W.H.I. Parren Richard W.J. Groen Sonja Zweegman Ellen Schrama Tom H. M. Ottenhoff
Cited by: Hematology Immunology Oncology
Journals: Blood (58 papers)Clinical Cancer Research (13 papers)The Journal of Immunology (7 papers)
Partner nations: Netherlands United States Denmark

In The Last Decade

Tuna Mutis

174 papers receiving 9.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Tuna Mutis

Since Specialization

Citations

This map shows the geographic impact of Tuna Mutis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuna Mutis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuna Mutis more than expected).

Fields of papers citing papers by Tuna Mutis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuna Mutis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuna Mutis. The network helps show where Tuna Mutis may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tuna Mutis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tuna Mutis Line = papers co-authored together Tuna Mutis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T‐cell therapy HemaSphere ·Kimitaka KAKITA,Hardy T.G.,Renée Poels,Francesca Vadurro,Hernando Durán Castro,L. Roskovcová,Jennemiek van Arkel,Recep Doğan,Niels W.C.J. van de Donk,Maria Themeli,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht,Rebecca M. Richards,Tuna Mutis	2025	0
2	A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy Blood ·T.H. Urlings,S Grisaru-Granovski,Carolien Duetz,K. Raghavendra,Robert G. Felt,Vladimíra Kábelová,Christie P.M. Verkleij,造地免田,Irfan A. Sheik,Kinichiro Tatebayashi,ندا کردونی,Yrd.doç.dr. Murat YENİSEY,Pieter Sonneveld,Philippe Moreau,Jürgen Claesen,Yukio Tamura,Sonja Zweegman,Tuna Mutis	2025	0
3	T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma Clinical Cancer Research ·Christie P.M. Verkleij,Saygin Abdikan,Marloes E.C. Broekmans,Kristine A. Frerichs,T.H. Urlings,Carolien Duetz,Jun Chida,S. Rubina Baglio,Sheri Skerget,Rocío Montes de,Sonja Zweegman,Raluca Verona,Tuna Mutis,Niels W.C.J. van de Donk	2024	25
4	Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma Journal for ImmunoTherapy of Cancer ·Robert G. Felt,Saygin Abdikan,乌立晖,Irfan A. Sheik,ندا کردونی,Christie P.M. Verkleij,Diane Le Clerre,Maria Themeli,Isabelle Chion-Sotinel,Sonja Zweegman,Román Galetto,Tuna Mutis,Niels W.C.J. van de Donk	2024	5
5	Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138 Clinical Cancer Research ·Kimitaka KAKITA,Hernando Durán Castro,Jennemiek van Arkel,Haridayal Jaswal,Afroditi Katsarou,Ruud Ruiter,Carlos Bryan-Jiménez,Huipin Yuan,Joost D. de Bruijn,Sonja Zweegman,Niels W.C.J. van de Donk,Richard W.J. Groen,Maria Themeli,Tuna Mutis	2023	10
6	Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity EBioMedicine ·Ida H. Hiemstra,Kim C. M. Santegoets,Maarten L. Janmaat,Bart E.C.G. de Goeij,S M Javad Hoseyni,益博山本,Péter Boross,Alireza Nojoumi,Sieto Bosgra,Matej Sedlar,F. V. Podsypanin,Dennis Verzijl,Richard G. Hibbert,Kristine A. Frerichs,Tuna Mutis,Niels W.C.J. van de Donk,Tahamtan Ahmadi,David Satijn,A. Kate Sasser,Esther C.W. Breij	2023	18
7	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis Clinical Cancer Research ·Š Špatenka,Kimitaka KAKITA,Afroditi Katsarou,Renée Poels,Erica Nogueira Fabro,Esther Drent,Eugeniy Butkov,Fengzhi Li,Sonja Zweegman,Niels W.C.J. van de Donk,Maria Themeli,Richard W.J. Groen,Tuna Mutis	2021	47
8	Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma Blood Advances ·Kristine A. Frerichs,Monique C. Minnema,Mark‐David Levin,Annemiek Broijl,Gerard M.J. Bos,Marie José Kersten,Tuna Mutis,Christie P.M. Verkleij,Inger S. Nijhof,Bwalya Simunyola,Saskia K. Klein,Sonja Zweegman,Pieter Sonneveld,Niels W.C.J. van de Donk	2021	27
9	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients Cancers ·Kristine A. Frerichs,Christie P.M. Verkleij,Meletios Α. Dimopoulos,F. H. Garner,Sonja Zweegman,Mary H. Young,Kathryn J. Newhall,Tuna Mutis,Niels W.C.J. van de Donk	2021	17
10	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma Blood Advances ·Christie P.M. Verkleij,Marloes E.C. Broekmans,Mark van Duin,Kristine A. Frerichs,Rowan Kuiper,Vladimíra Kábelová,Martin Kaiser,Gareth J. Morgan,Amy Axel,Rengasamy Boominathan,Jocelyn Sendecki,Amy P. Wong,Raluca Verona,Pieter Sonneveld,Sonja Zweegman,Homer Adams,Tuna Mutis,Niels W.C.J. van de Donk	2021	117
11	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma Journal of Clinical Medicine ·Devi Indrawati Syafei,Christie P.M. Verkleij,J Jeziorski,Kristine A. Frerichs,Tuna Mutis,Sonja Zweegman,Niels W.C.J. van de Donk	2021	17
12	Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab Clinical Cancer Research ·Kristine A. Frerichs,Marloes E.C. Broekmans,F. H. Garner,Berris van Kessel,Martijn W. Heymans,Š Špatenka,Christie P.M. Verkleij,Rengasamy Boominathan,Bhavesh Vaidya,Jocelyn Sendecki,Amy Axel,François Gaudet,Kodandaram Pillarisetti,Sonja Zweegman,Homer Adams,Tuna Mutis,Niels W.C.J. van de Donk	2020	68
13	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies Cancers ·Christie P.M. Verkleij,Deping Zhai,Marloes E.C. Broekmans,Kristine A. Frerichs,Sonja Zweegman,Tuna Mutis,Natalie Bezman,Niels W.C.J. van de Donk	2020	26
14	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells Clinical Cancer Research ·Esther Drent,Renée Poels,Ruud Ruiter,Niels W.C.J. van de Donk,Sonja Zweegman,Huipin Yuan,Joost D. de Bruijn,Michel Sadelain,Henk M. Lokhorst,Richard W.J. Groen,Tuna Mutis,Maria Themeli	2019	135
15	T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells Cancer Immunology Research ·Margot J. Pont,Rimke Oostvogels,Cornelis A.M. van Bergen,Edith D. van der Meijden,Dayu Dian Perwatasari,M Kimura,Marlieke L.M. Jongsma,Henk M. Lokhorst,J.H. Frederik Falkenburg,Tuna Mutis,Marieke Griffioen,Robbert M. Spaapen	2019	8
16	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Clinical Cancer Research ·Jakub Krejcik,Abbas Ghasemihamed,Inger S. Nijhof,Berris van Kessel,Jeroen F. van Velzen,Andries C. Bloem,Marloes E.C. Broekmans,Sonja Zweegman,Johan van Meerloo,René J.P. Musters,Pino J. Poddighe,Richard W.J. Groen,Christopher Chiu,Torben Plesner,Henk M. Lokhorst,A. Kate Sasser,Tuna Mutis,Niels W.C.J. van de Donk	2017	119
17	Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding Blood ·Hilma J. van der Horst,Marije B. Overdijk,Esther C.W. Breij,Martine E.D. Chamuleau,Henk M. Lokhorst,Tuna Mutis	2017	4
18	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma Blood ·Inger S. Nijhof,Tineke Casneuf,段志慧,Berris van Kessel,Amy Axel,Khaja Syed,Richard W.J. Groen,Mark van Duin,Pieter Sonneveld,Monique C. Minnema,Sonja Zweegman,Christopher Chiu,Andries C. Bloem,Tuna Mutis,Henk M. Lokhorst,A. Kate Sasser,Niels W.C.J. van de Donk	2016	275
19	Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells Clinical Cancer Research ·Teun Guichelaar,Maarten E. Emmelot,Henk Rozemuller,Trojan Sj,Richard W.J. Groen,Gert Storm,Henk M. Lokhorst,Anton C. Martens,Tuna Mutis	2013	22
20	Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance Clinical Cancer Research ·Sharli Mudaliyar,Niels W.C.J. van de Donk,Monique C. Minnema,Julie H. Huang,Tineke Aarts‐Riemens,Niels Bovenschen,Huipin Yuan,Richard W.J. Groen,Douglas W. McMillin,Jana Jakubı́ková,Henk M. Lokhorst,Anton C. Martens,Constantine S. Mitsiades,Tuna Mutis	2013	51

About Tuna Mutis

Tuna Mutis is a scholar working on Hematology, Immunology, Oncology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 180 papers that have together received 9.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (66 papers), Immune Cell Function and Interaction (60 papers), CAR-T cell therapy research (54 papers), Immunotherapy and Immune Responses (53 papers), T-cell and B-cell Immunology (41 papers), Monoclonal and Polyclonal Antibodies Research (34 papers), Peptidase Inhibition and Analysis (18 papers) and Hematopoietic Stem Cell Transplantation (18 papers). The work is most often cited by research in Hematology (4.2k citations), Immunology (4.7k citations), Oncology (4.1k citations), Physiology (527 citations) and Genetics (822 citations). Tuna Mutis has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Niels W.C.J. van de Donk, Els Goulmy, Henk M. Lokhorst, Paul W.H.I. Parren, Richard W.J. Groen, Sonja Zweegman, Ellen Schrama, Tom H. M. Ottenhoff, Inger S. Nijhof and Anton C. Martens. Their work appears in journals such as Blood, Clinical Cancer Research, The Journal of Immunology, Haematologica and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact